menu toggle

HTA Quarterly | Fall 2022

By HTA Quarterly

In this issue, our editors provide insights on the new European Union health technology assessment (HTA) regulation, an analysis of the use of health economics to respond to the COVID-19 pandemic, and a review of Germany’s newly adopted Statutory Health Insurance Financial Stabilization Act.

EU Flag HTA Assessments

HTA Quarterly | Fall 2022

The new EU regulation on health technology assessment: Major change or minor adjustment?

The new 2022 European Union (EU) health technology assessment (HTA) regulation is intended to streamline assessment of clinical data across the EU and minimize duplication of effort, for both health technology developers and HTA bodies. We consider what the new regulation means for health technology developers, particularly in terms of evidence submission requirements and what can be done to influence the implementation of the new regulation.
ben franklin bill wearing mask

HTA Quarterly | Fall 2022

Did health economics fail us during the COVID-19 pandemic?

Are the measures taken to manage COVID-19 cost-effective? Should this question even be raised when lives are at stake? In reality, budgets are finite and cost-benefit decisions are taken by healthcare policy makers every day to prioritize resources. So, did health economics step up to the plate during the COVID-19 pandemic?

Reform in front of money

HTA Quarterly | Fall 2022

Upcoming cost-containing measures in Germany—How will they affect the biopharmaceutical industry?

Multiple factors have combined to create a large and growing deficit in statutory health insurance (SHI) contribution revenue vs healthcare expenditures in Germany. In this article, we consider whether the new proposed SHI Financial Stabilization Act will deliver the structural reforms needed to reverse this trend, focusing specifically on measures affecting the biopharmaceutical industry.
image of a patient with alopecia areata

Xcenda original research on alopecia areata

image of a patient with alopecia areata

It’s bigger than the US: A global perspective on alopecia areata

Alopecia areata (AA), an autoimmune disease that may result in hair loss, affects any gender and all skin types. Approximately 0.1%–0.58% of the world’s population is diagnosed with AA. AA is unpredictable and found to be more prevalent in younger age groups. The more extensive the hair loss becomes, the more likely the disease will become chronic and not remit without treatment. Thinking of AA as simply hair loss fails to acknowledge the suffering experienced by many patients.

Prior to the recent approval of the first Janus kinase (JAK) inhibitor for AA, there were no regulatory-approved treatments available for patients with AA. This results in high out-of-pocket cost for patients on top of their already high financial, psychological, and social burden.

Xcenda took a global perspective on AA and examined the steps needed to manage the major life impact AA has on patients. As medical science progresses in developing a treatment for AA, payers and policymakers should recognize that AA may have severe and lifelong psychological, emotional, and other impacts on patients. The paper addresses actions to ensure appropriate and equitable access to treatments once they become available. 

image of a patient with alopecia areata

HTA by the numbers

Annual cap for pharmacy costs for 50 million Americans with Medicare Part D (drug coverage) as part of the August 2022 US Inflation Reduction Act

Heard on the street

speech bubble icon
“Health leaders are clear that unless urgent action [limiting energy price increases for individuals in need] is taken by the government, this will cause a public health emergency.”
- Matthew Taylor, chief executive of the NHS Confederation, after senior public health figures in England, Wales, and Northern Ireland penned a letter to the government warning that rising energy costs will worsen health inequalities